These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 12388623

  • 1. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
    Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, Coy DH, Jensen RT.
    J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
    [Abstract] [Full Text] [Related]

  • 2. Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig.
    Igarashi H, Ito T, Hou W, Mantey SA, Pradhan TK, Ulrich CD, Hocart SJ, Coy DH, Jensen RT.
    J Pharmacol Exp Ther; 2002 Apr; 301(1):37-50. PubMed ID: 11907155
    [Abstract] [Full Text] [Related]

  • 3. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
    Dickson L, Aramori I, McCulloch J, Sharkey J, Finlayson K.
    Neuropharmacology; 2006 Nov; 51(6):1086-98. PubMed ID: 16930633
    [Abstract] [Full Text] [Related]

  • 4. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
    Vertongen P, Langlet C, Langer I, Gaspard N, Robberecht P.
    Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
    [Abstract] [Full Text] [Related]

  • 5. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
    Nachtergael I, Vertongen P, Langer I, Perret J, Robberecht P, Waelbroeck M.
    Biochem J; 2003 Mar 15; 370(Pt 3):1003-9. PubMed ID: 12475394
    [Abstract] [Full Text] [Related]

  • 6. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors.
    Igarashi H, Ito T, Mantey SA, Pradhan TK, Hou W, Coy DH, Jensen RT.
    J Pharmacol Exp Ther; 2005 Oct 15; 315(1):370-81. PubMed ID: 15994369
    [Abstract] [Full Text] [Related]

  • 7. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
    Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.
    Mol Pharmacol; 1999 Dec 15; 56(6):1280-7. PubMed ID: 10570056
    [Abstract] [Full Text] [Related]

  • 8. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
    Van Rampelbergh J, Juarranz MG, Perret J, Bondue A, Solano RM, Delporte C, De Neef P, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2000 Jun 15; 130(4):819-26. PubMed ID: 10864888
    [Abstract] [Full Text] [Related]

  • 9. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
    Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2001 Aug 15; 133(8):1249-54. PubMed ID: 11498510
    [Abstract] [Full Text] [Related]

  • 10. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM, Goursaud S, Medja F, Lelièvre V, Mounien L, Husson I, Brabet P, Jégou S, Janet T, Gressens P.
    J Pharmacol Exp Ther; 2005 Aug 15; 314(2):745-52. PubMed ID: 15872042
    [Abstract] [Full Text] [Related]

  • 11. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S, Latini S, Barberi M, Teti A, Stefanini M, Canipari R.
    J Endocrinol; 2006 Oct 15; 191(1):287-99. PubMed ID: 17065411
    [Abstract] [Full Text] [Related]

  • 12. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity.
    Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT.
    Peptides; 2001 Jul 15; 22(7):1139-51. PubMed ID: 11445245
    [Abstract] [Full Text] [Related]

  • 13. Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.
    Perret J, Vertongen P, Solano RM, Langer I, Cnudde J, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2002 Aug 15; 136(7):1042-8. PubMed ID: 12145104
    [Abstract] [Full Text] [Related]

  • 14. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG, De Neef P, Robberecht P.
    Prostate; 1999 Sep 15; 41(1):1-6. PubMed ID: 10440869
    [Abstract] [Full Text] [Related]

  • 15. Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction.
    Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, Waelbroeck M.
    J Biol Chem; 2001 Jan 12; 276(2):1084-8. PubMed ID: 11013258
    [Abstract] [Full Text] [Related]

  • 16. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M.
    J Biol Chem; 2000 Aug 04; 275(31):24003-12. PubMed ID: 10801840
    [Abstract] [Full Text] [Related]

  • 17. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
    Nachtergael I, Gaspard N, Langlet C, Robberecht P, Langer I.
    Cell Signal; 2006 Dec 04; 18(12):2121-30. PubMed ID: 16650965
    [Abstract] [Full Text] [Related]

  • 18. Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
    Langer I, Langlet C, Robberecht P.
    J Mol Endocrinol; 2005 Apr 04; 34(2):405-14. PubMed ID: 15821106
    [Abstract] [Full Text] [Related]

  • 19. Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding.
    Nicole P, Maoret JJ, Couvineau A, Momany FA, Laburthe M.
    Biochem Biophys Res Commun; 2000 Sep 24; 276(2):654-9. PubMed ID: 11027527
    [Abstract] [Full Text] [Related]

  • 20. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
    Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Peptides; 2000 Oct 24; 21(10):1543-9. PubMed ID: 11068102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.